Clesrovimab Significantly Reduces RSV in Infants
Merck, known as MSD outside of the United States and Canada, announced positive results from their Phase 2b/3 clinical...
Jon Napitupulu
Actineer Begins Actinium-225 Production
Actineer, a joint venture between ITM and Canadian Nuclear Laboratories (CNL) Ltd., has successfully produced Actinium-225 (Ac-225) by irradiating...
Expert Strategies for FDA LDT Compliance: Meeting the 1st Milestone
Clinical laboratories face a critical deadline: achieving Phase One compliance with the FDA’s Laboratory Developed Test (LDT) rule by...
Charles River Launches New Retrogenix® Protein Library
Charles River Laboratories International, Inc. has introduced the Retrogenix® Non-Human Protein Library, a tool designed to assist biopharmaceutical companies...
AN2 Receives Grant for Boron-Based Therapies for Tuberculosis
AN2 Therapeutics, a biopharmaceutical company specializing in boron chemistry-based therapeutics, has secured continued research funding from the Bill &...
Cefiderocol Shows Strong Clinical Response in Global Study
Shionogi & Co., Ltd. has released new data from PROVE, a large-scale global study examining real-world evidence for Fetroja®/Fetcroja®...